MetaCap

Absci (ABSI) vs MaxCyte (MXCT)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Absci (ABSI) has outperformed MaxCyte (MXCT) over the past year, gaining 156.3% versus a loss of 18.0%. Over five years, ABSI leads with a -31.8% price change compared with -85.9% for MXCT. Absci is the larger company by market cap ($1.30 billion vs $141.5 million), about 9.2 times the size, while MaxCyte is growing revenue faster (-14.5% vs -38.2%).

MaxCyte converts more of its revenue into profit, with a net margin of -135.1% versus -4113.7%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ABSI+156.31%MXCT-17.96%
+332%+127%-78%
Nov 21, 20251 yearNov 20, 2026
ABSI-32.04%MXCT-89.29%
+10%-45%-100%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ABSI versus MXCT key metrics
MetricABSIMXCT
Share price$7.51$1.37
Market cap$1.30B$141.45M
1-day change-7.97%+7.03%
YTD return+115.19%-11.61%
1-year return+156.31%-17.96%
5-year return-31.79%-85.92%
EPS (TTM)$-0.79$-0.26
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$2.80M$33.03M
Revenue growth (YoY)-38.24%-14.50%
Net income (latest FY)$-115.18M$-44.63M
Gross margin—81.16%
Operating margin-4297.04%-157.14%
Net margin-4113.68%-135.14%
52-week high$12.55$1.80
52-week low$2.24$0.643
Distance from 52-week high-40.14%-23.89%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+100.93%+200.00%
Average volume4.08M1.04M
Shares outstanding172.75M103.25M
Employees14091
SectorHealth CareHealth Care
IndustryBiotechnology: Commercial Physical & Biological ResarchBiotechnology: Commercial Physical & Biological Resarch

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Absci is about 9.2 times larger than MaxCyte by market value ($1.30B vs $141.45M).
  • ABSI has outperformed MXCT by 174.3 percentage points over the past year.
  • MaxCyte is more profitable, keeping -135.1 cents of every revenue dollar as net income versus -4113.7 cents for Absci.
  • MaxCyte grew revenue faster in its latest fiscal year (-14.50% vs -38.24%).

About Absci

ABSI stock →

Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; ABS-201, an anti-prolactin receptor (PRLR) antibody, which is phase 1/2a clinical trial for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology.

Health Care · Biotechnology: Commercial Physical & Biological Resarch · 140 employees

About MaxCyte

MXCT stock →

MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.

Health Care · Biotechnology: Commercial Physical & Biological Resarch · 91 employees

ABSI vs MXCT FAQ

Which is bigger, Absci or MaxCyte?

Absci (ABSI) is larger, with a market capitalization of $1.30B compared with $141.45M for MaxCyte (MXCT).

Which stock has performed better over the past year, ABSI or MXCT?

ABSI returned +156.31% over the past 12 months, compared with -17.96% for MXCT (price return, excluding dividends). Past performance does not predict future results.

Are Absci and MaxCyte in the same industry?

Yes. Both are classified in the Biotechnology: Commercial Physical & Biological Resarch industry within the Health Care sector.

More comparisons